United States· US:0054-0711_db72caee-70a3-4561-b855-08b4c9f4a0e0
Deferiprone
A deferiprone product containing deferiprone, registered in United States by Hikma Pharmaceuticals USA Inc.. The same ATC class is registered in 16 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Deferiprone is registered in 16 of 19 countries.
Countries holding a registration under ATC V03AC02 (deferiprone), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Deferiprone · ATC V03AC02
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of deferiprone costs, country by country.
Normalised to the WHO defined daily dose (5.25 g), the median price runs from $22.61 in Switzerland to $8636.08 in Italy — a ×382 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Deferiprone · price per daily dose (5.25 g)
USD · FX 28 Sept 2026
- IT Italy$8636.08
- CH Switzerland$22.61
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DEFERIPRONE
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Country
- United States (US)
- ATC code
- V03AC02
- ATC class
- Deferiprone
- Defined daily dose
- 5.25 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 6
- ndc11005407111950 TABLET, COATED in 1 BOTTLE (0054-0711-19)
- ndc110054071123150 TABLET, COATED in 1 BOTTLE (0054-0711-23)
- ndc110054071128300 TABLET, COATED in 1 BOTTLE (0054-0711-28)
- ndc110054-0711-19
- ndc110054-0711-23
- ndc110054-0711-28
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
315 interactions on record for deferiprone.
Graded by severity as the source publishes them — 266 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Deferiprone · interactions on record
315 records
- 266 severe
- 49 moderate
Most severe, free to view
- FostamatinibB02BX09severe
- ProcainamideC01BA02severe
- TocainideC01BB03severe
- PropylthiouracilH03BA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Deferiprone in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomDeferiprone 400mg capsulesPfertec Ltd
- SwedenDeferipron Ebb 1000 mg Filmdragerad tablettEbb Medical AB
- FranceDEFERIPRONE ARROW 1000 mg, comprimé pelliculé sécableARROW GENERIQUES
- ItalyDEFERIPRONE DOCDOC GENERICI S.R.L.
- CzechiaDEFERIPRONE LIPOMEDLipomed GmbH, Weil am Rhein
- CanadaFERRIPROXCHIESI CANADA CORP.
- IrelandDeferiprone Lipomed 500 mg Film-coated tabletLipomed GmbH
- FinlandDeferiprone LipomedLipomed GmbH
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Cyprus · Deferiprone Sapiens
- Denmark · Deferipron Orifarm
- France · Deferiprone Arrow
- United Kingdom (Northern Ireland) · Deferiprone Mercury Pharmaceuticals, Deferiprone Mercury Pharmaceuticals Ltd.
- Greece · Befeprox
- Iceland · Ferriprox
- Italy · Deferiprone Doc
- Liechtenstein · Ferriprox
- Norway · Ferriprox
- Portugal · Befeprox, Deferriprona Generis
- Sweden · Deferipron Evolan, Deferiprone Doc
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf40f7fa-fdaf-45db-9659-16b7a9b85ebb GET /v1/drugs/bf40f7fa-fdaf-45db-9659-16b7a9b85ebb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "1000",
"substance": "DEFERIPRONE",
"productndc": "0054-0711",
"dosage_form": "TABLET, COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA213239",
"marketing_category": "ANDA"
}See everything about deferiprone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.